FDA Grants Priority Review for NUPLAZID Supplement NDA210793
The FDA has granted priority review status for the supplemental NDA for NUPLAZID, an indication for pimavanserin tartrate.
Company
Pharmaceutical intelligence for ACADIA PHARMS INC. with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.